Teva Pharmaceutical Industries (TEVA) reported Q4 non-GAAP earnings Wednesday of $0.71 per diluted share, down from $1.00 a year earlier.
Analysts polled by FactSet expected $0.71.
Net revenue for the quarter ended Dec. 31 was $4.23 billion, down from $4.46 billion a year earlier.
Analysts surveyed by FactSet expected $4.15 billion.
For 2025, the drug maker said it expects non-GAAP diluted EPS of $2.35 to $2.65 on revenue of $16.8 billion to $17.4 billion. Analysts polled by FactSet expect non-GAAP EPS of $2.96 on revenue of $17.09 billion.
Teva shares were down by more than 5% in premarket trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。